GSK3 Inhibition Los ntawm Phosphorylation Ntawm Ser389 Tswj Neuroinflamation
Oct 24, 2023
Abstract: Qhov inhibition ntawm Glycogen Synthase Kinase 3 (GSK3) los ntawm Ser9 phosphorylation cuam tshuam rau ntau cov txheej txheem physiological, suav nrog kev tiv thaiv kab mob. Txawm li cas los xij, qhov tshwm sim ntawm GSK3 inhibition los ntawm lwm txoj Ser389 phosphorylation tseem tsis zoo. Ntawm no peb tau soj ntsuam neuroinflammation nyob rau hauv GSK3 Ser389 knock-in (KI) nas, nyob rau hauv uas phosphorylation ntawm Ser389 GSK3 yog impaired. Tus naj npawb ntawm activated microglia / infiltrated macrophages, astrocytes, thiab infiltrated neutrophils tau ntau dua nyob rau hauv cov tsiaj no piv rau C57BL / 6J qus-hom (WT) counterparts, uas qhia tias tsis ua hauj lwm rau inactivate GSK3 los ntawm Ser389 phosphorylation ua nyob rau hauv cov qib qis. neuroinflamation. Ntxiv mus, glial cell activation thiab hlwb infiltration ntawm lub cev tiv thaiv kab mob nyob rau hauv teb rau lipopolysaccharide (LPS) ua tsis tau tejyam nyob rau hauv GSK3 Ser389 KI nas. Cov teebmeem no yog lub hlwb tshwj xeeb, vim tias kev tiv thaiv kab mob peripheral tsis zoo ib yam. Tsis tas li ntawd, phosphorylation ntawm IkB kinase complex (IKK) nyob rau hauv cov lus teb rau LPS ua tsis tau tejyam nyob rau hauv GSK3 Ser389 KI nas, thaum STAT3 phosphorylation tau txais kev cawmdim, qhia tias txoj kev NF-κB qhia tshwj xeeb yog cuam tshuam los ntawm GSK3 txoj kev tswj hwm. Zuag qhia tag nrho, peb qhov kev tshawb pom qhia tias GSK3 inactivation los ntawm Ser389 phosphorylation tswj lub hlwb inflammatory teb, tsa qhov yuav tsum tau soj ntsuam nws lub luag hauj lwm nyob rau hauv kev loj hlob ntawm neuroinflammatory pathologies.

cistanche tubulosa - Anti-inflammatory
Ntsiab lus: neuroinflamation; microglia; astrocytes; neutrophils; NF-κB signaling; flow cytometry

Cistanche tshuaj ntsuab ua dab tsi - Anti- mob
Nyem qhov no mus saib Cistanche cov khoom
【Nug ntxiv】Email: cindy.xue@wecistanche.com / Whats App: 0086 18599088692 / Wechat: 18599088692
1. Taw qhia
Glycogen Synthase Kinase 3 (GSK3) yog ib qho serine-threonine kinase nrog dav dav. GSK3 tswj cov txheej txheem ntau yam xws li mob, kev loj hlob ntawm tes, kev sib txawv ntawm tes, thiab lub zog metabolism thiab cuam tshuam rau cov kab mob hnub nyoog xws li ntshav qab zib, Alzheimer's disease, thiab mob cancer [1]. Ob leeg GSK3 isoforms, GSK3 thiab GSK3 , tau nthuav tawm ubiquitously, tab sis lawv cov dej num tsis tag nrho sib tshooj [2]. GSK3 yog qhov tseem ceeb, txawm hais tias nws cov haujlwm tuaj yeem cuam tshuam los ntawm kev sib cais rau hauv cytosolic complexes nrog rau phosphorylation ntawm residues Ser9 thiab Ser389 [3]. Akt-induced phosphorylation ntawm GSK3 ntawm Ser9 yog GSK3 txoj kev tswj hwm tam sim no nyob rau hauv feem ntau ntawm tes, thiab nws yog txoj hauv kev los txwv GSK3 ua kom muaj zog thiab tiv thaiv kev tuag ntawm tes. Hauv qhov sib piv, peb tau pom tias p38 MAPK-induced Ser389 phosphorylation yog txwv rau cov ntaub so ntswg xws li lub hlwb, thymus, thiab spleen [4] thiab lub hlwb qhia ntawm phospho-Ser389 GSK3 yog kev txhim kho kev tswj hwm [5]. Lub phosphorylation ntawm GSK3 los ntawm Ser389 yog tshwm sim feem ntau los ntawm DNA ob-strand so cov lus teb thiab nws yog ib qho tseem ceeb kom cia DNA kho [6,7]. Yog li, thaum phosphorylation ntawm Ser9 yog txoj hauv kev tseem ceeb rau kev tsis ua haujlwm ntawm cytoplasmic GSK3, Ser389 phosphorylation yog siv los ua kom tsis muaj zog ntawm lub pas dej nuclear ntawm GSK3 kom muaj sia nyob thaum kho DNA DSB [8]. Kev tsis ua haujlwm GSK3 los ntawm Ser389 phosphorylation hauv kev teb rau DSB ua rau muaj kev tuag ntawm tes los ntawm necroptosis [6,7]. Qhov no tseem ceeb heev vim hais tias hom necroptotic ntawm kev tuag yog ntau inflammatory thiab tau pom nyob rau hauv inflammatory kab mob [9]. Txawm li cas los xij, tsis zoo li phosphorylation ntawm Ser9, qhov cuam tshuam ntawm phosphorylation ntawm GSK3 ntawm Ser389 tseem tsis zoo. Ntau cov kev tshawb fawb tau txhawb nqa kev koom tes ntawm GSK3 thiab mob. Yog li, ua kom GSK3 los ntawm inflammatory stimuli xws li kev ntxhov siab, kab mob, los yog kev raug mob txhawb kev tsim cov pro-inflammatory cytokines xws li IL-6, IL-1 , thiab IFN , thaum GSK3 inhibition suppresses cov synthesis ntawm pro-inflammatory mediators thiab nce IL-10 ntau lawm los ntawm lub cev tiv thaiv kab mob [10]. GSK3 tuaj yeem qhib tau los ntawm lipopolysaccharide (LPS), yog ib qho ntawm cov kab mob tseem ceeb ntawm cov kab mob Gram-negative [11,12]. Raws li kev khi ntawm cov kab mob LPS rau Tus Xov Tooj Zoo li receptors (TLRs), GSK3 kho qhov tso tawm ntawm cov kab mob cytokines hauv cov hlwb ntawm lub cev tsis muaj zog [13]. Tsis tas li ntawd, nws tau raug tshaj tawm tias kev tswj hwm ntawm GSK3 inhibitors rau cov nas uas tau kho nrog cov tshuaj tua kab mob LPS ua rau cov tsiaj muaj sia nyob [14]. Txawm hais tias cov teebmeem pro-inflammatory cuam tshuam nrog GSK3, cov teebmeem tiv thaiv kab mob kuj tau sau tseg [15,16]. Yog li, GSK3 txoj cai tseem ceeb heev rau kev tswj hwm qhov sib npaug ntawm cov pro- thiab cov tshuaj tiv thaiv cytokines tom qab TLR ua kom [17]. Nuclear factor kB (NF-kB) mediates tsim cov pro-inflammatory cytokines thiab yog ib qho ntawm cov ntsiab lus tseem ceeb uas qhib los ntawm TLRs. Ntau tus kws sau ntawv tau lees paub tias GSK3 tuaj yeem qhib NF-kB teeb liab los ntawm phosphorylation ntawm IkB kinase complex (IKK), uas phosphorylates IkB thiab tso tawm NF-kB nquag. Lwm qhov kev hloov pauv ntawm phosphorylated los ntawm GSK3 yog lub teeb liab transducer thiab activator ntawm transcription-3 (STAT3), uas kho cov neuroinflammation nyob rau hauv cov ntsiab lus ntawm septic shock [18]. STAT3 phosphorylation los ntawm GSK3 ua rau muaj kev hloov pauv hauv nuclear thiab ua kom muaj zog. Tsis tas li ntawd, GSK3 inhibits anti-inflammatory CREB thiab AP-1 kev ua haujlwm ntawm kev hloov pauv, ua kom nthuav dav cov lus qhia ntawm proinflammatory cytokines [10,19]. Microglia hlwb yog cov neeg nyob hauv macrophages hauv CNS. Ua ke nrog infiltrated leukocytes, microglia activation plays lub luag haujlwm tseem ceeb hauv neuroinflamation. Astrocytes kuj yog cov hlwb glial nrog cov haujlwm neuroimmune thaum lawv sib tham nrog microglia, leukocytes, thiab endothelial hlwb, yog li hloov kho ob qho tib si hauv lub cev thiab hloov lub cev tiv thaiv kab mob [20]. Kev ua kom microglia thiab astrocytes nyob rau hauv cov lus teb rau inflammatory stimuli (gliosis) yog tus cwj pwm los ntawm cov cellular hloov loj uas muaj xws li proliferation, hypertrophy, thiab cytokine tso [21]. GSK3 tau koom nrog hauv kev txhim kho gliosis hauv kev teb rau LPS lossis los ntawm kev tshaj tawm ntawm neural GSK3 [22]. Tseem muaj pov thawj tias glial reactivity thiab neuroinflammation induced los ntawm GSK3 tuaj yeem kho los ntawm kev ua kom NF-kB txoj hauv kev hauv hlwb [19,23]. Nyob rau hauv sib piv, qhov inactivation ntawm GSK3 txo glial reactivity, txwv cov neuroinflammatory teb, thiab tsub kom cov anti-inflammatory CREB kev ua si nyob rau hauv neural hlwb [24]. Yog li ntawd, nws tau pom zoo tias GSK3 ua lub luag haujlwm tseem ceeb hauv kev loj hlob ntawm cov kab mob neuroinflammatory, xws li Alzheimer's kab mob thiab ntau yam sclerosis [25]. Phosphorylation yog ib qho kev tswj hwm ntawm GSK3 kev ua haujlwm nrog qhov cuam tshuam loj rau kev tswj lub cev tiv thaiv kab mob. Yog li, GSK3 inhibition los ntawm classical Ser9 phosphorylation upregulates zus tau tej cov anti-inflammatory mediators thiab downregulates qhov kev tso tawm ntawm pro-inflammatory cytokines [26], txawm hais tias nws kuj yog koom nyob rau hauv kev daws teeb meem ntawm o nyob rau hauv ib tug qauv ntawm kev sim colitis induced los ntawm trinitrobenzene sulfonic acid. [27]. Nyob rau hauv lub hlwb, qhov tsis zoo inhibition ntawm GSK3 los ntawm Ser9 phosphorylation tau cuam tshuam rau inflammatory neuropathologies xws li Parkinson's disease [28] thiab schizophrenia [29]. Nyob rau hauv sib piv, txawm tias cov qib siab ntawm phospho-Ser389 GSK3 pom nyob rau hauv lub hlwb [4], nws tseem tsis tau paub seb txoj kev no rau inactivation ntawm GSK3 plays lub luag hauj lwm nyob rau hauv tuning neuroinflammation. Ntawm no, peb tshawb xyuas lub luag haujlwm ntawm Ser389 phosphorylation-mediated GSK3 inactivation hauv neuroinflammation siv GSK3 KI nas uas GSK3 Ser389 tau hloov los ntawm Ala los tiv thaiv C-terminal phosphorylation ntawm GSK3 [7,8]. Peb cov txiaj ntsig tau qhia tias qhov tsis ua haujlwm ntawm GSK3 los ntawm phosphorylation ntawm Ser389 nyob rau hauv cov xwm txheej ntawm lub cev ua rau cov kab mob qis qis thiab tsis muaj lus teb rau inflammatory stimuli xws li LPS. Qhov mob mob ntev no zoo li tshwj xeeb rau lub hlwb vim tias lub cev tiv thaiv kab mob peripheral tsis cuam tshuam ntau. Peb kuj qhia tau hais tias tsis muaj phospho-Ser389 GSK3 nyob rau hauv lub hlwb ntawm GSK3 KI nas tswj NF-kB signaling, uas yog ib qho tseem ceeb tshwm sim nyob rau hauv kev tswj ntawm neuroinflamation. Yog li, peb qhov kev tshawb pom muab kev txhawb nqa rau kev koom tes ntawm GSK3 inactivation los ntawm Ser389 phosphorylation hauv inflammatory neuropathologies.
2. Cov txiaj ntsig
2.1. Kev tsis ua haujlwm GSK3 los ntawm Ser389 Phosphorylation Ua rau nce basal Neuroinflamation
Inactivation ntawm GSK3 los ntawm phosphorylation ntawm Ser9 tau cuam tshuam nrog kev tiv thaiv kab mob hauv lub hlwb [30]. Txawm hais tias qhov inactivation ntawm GSK3 los ntawm phosphorylation ntawm Ser389 yog ib qho tseem ceeb los txo cov neuronal tuag los ntawm DNA ob-strand so nyob rau hauv lub hlwb, tsis muaj kev tshawb fawb tau tshawb xyuas seb txoj kev no tseem tuaj yeem tswj cov lus teb neuroinflammatory. Peb, yog li ntawd, siv cov GSK3 Ser389 KI cov nas uas tau piav dhau los, uas Ser389 tau hloov los ntawm Ala, txhawm rau tiv thaiv Ser389 phosphorylation. Peb tau tshuaj xyuas cov neeg nyob hauv thiab infiltrated lub cev tiv thaiv kab mob hauv tag nrho lub hlwb (tshwj tsis yog cerebellum thiab olfactory qhov muag teev) los ntawm WT thiab GSK3 Ser389 KI nas los ntawm cov neeg kho tshuab dissociation ntawm cov ntaub so ntswg thiab Percoll gradient, ua raws li cov txheej txheem ua ntej kom tau txais kev sib npaug ntawm cov neeg nyob hauv thiab cov hlwb infiltrated. hauv lub hlwb, suav nrog microglia / macrophages, astrocytes, infiltrated neutrophils thiab lymphocytes [31]. Cells raug soj ntsuam los ntawm kev khiav cytometry siv cov cim cim (Daim duab S1 hauv Cov Khoom Siv Ntxiv) [31–33]. Ua kom muaj zog thiab so microglia / macrophages tau txheeb xyuas raws li CD11b + CD45high thiab CD11b + CD45low, raws li txoj cai, thaum cov neeg lymphocytic tau cim tias CD45+CD11b− [32,34]. Neutrophils tau tus cwj pwm li CD45+Ly6G+ hlwb; thiab astrocytes tau txhais nyob rau hauv CD45- cov pej xeem los ntawm kev qhia ntawm cell nto antigen-2 (ACSA-2). Cov cim no yog siv rau kev tshawb pom ntawm kev loj hlob thiab cov neeg laus astrocytes [35]. Upregulation ntawm ACSA-2 tau pom nyob rau hauv reactive astrocytes txuam nrog inflammatory mob, xws li autoimmune demyelination [36]. Peb yav dhau los pom tias tus naj npawb ntawm ACSA-2+ astrocytes hauv nas hlwb nce ntxiv tom qab kev kho LPS, qhia ntxiv tias qib ntawm ACSA-2 qhia cuam tshuam nrog kev ua kom astrocyte hauv kev teb rau inflammatory stimuli [31]. Txawm hais tias ACSA-2 kuj tuaj yeem qhia tau nyob rau hauv me me subpopulation ntawm microglia thiab macrophages [35], cov hlwb no nyob hauv CD45+ cov pejxeem. Flow cytometry tsom xam ntawm lub hlwb ntawm tes cais los ntawm cov nas nyob rau hauv lub cev nqaij daim tawv tau qhia ib qho kev nce nyob rau hauv ib feem ntawm activated microglia / macrophages nyob rau hauv GSK3 Ser389 KI nas piv rau WT nas (Daim duab 1a). Hauv qhov sib piv, qhov feem pua ntawm cov microglia so tau txo qis hauv lub hlwb ntawm GSK3 Ser389 KI nas (Daim duab 1b). Tsis tas li ntawd, muaj qhov nce ntxiv ntawm qhov muaj ACSA-2+ astrocytes (piv txwv li, activated astrocytes) hauv GSK3 Ser389 KI nas (Daim duab 1c). Hais txog kev tiv thaiv kab mob hauv lub hlwb hauv lub hlwb, muaj qhov pom tseeb ntawm cov neutrophils nyob rau hauv lub hlwb ntawm GSK3 Ser389 KI nas txheeb ze rau WT nas (Daim duab 1d), qhia ntxiv tias muaj cov lus teb tsis tu ncua hauv lub hlwb ntawm GSK3 Ser389 KI nas nyob rau hauv lub cev. tej yam kev mob. Txawm li cas los xij, qhov zaus ntawm CD45+CD11b- leukocytes (feem ntau lymphocytic cells) hauv lub hlwb tsis cuam tshuam rau GSK3 Ser389 KI nas (Daim duab 1e). Ua ke, cov txiaj ntsig no qhia tau hais tias tsis ua rau GSK3 los ntawm phosphorylation ntawm Ser389 ua rau muaj kev mob tshwm sim hauv lub hlwb uas ua rau muaj kev cuam tshuam ntawm microglia thiab astrocytes.

Daim duab 1. Inactivation ntawm GSK3 los ntawm Ser389 phosphorylation cuam tshuam rau cov hlwb hlwb cuam tshuam nrog neuroinflamation. Lub hlwb los ntawm ob WT thiab GSK3 Ser389 KI nas raug tshem tawm thiab ua tiav rau kev ntsuas cytometry ntawm (a) CD11b++CD45high activated microglia/macrophages, (b) CD11b++CD45low so microglia, (c) ACSA -2+ astrocytes, (d) Ly6G+ neutrophils, thiab (e) CD11b- lymphocytes. Histograms sawv cev rau tus xov tooj ntawm tes, qhia raws li feem pua ntawm CD45- hlwb (astrocytes) lossis CD{16}} hlwb (tag nrho lwm cov pejxeem). Cov ntaub ntawv tau qhia tias txhais tau tias ± SEM (n=7–9). Cov tub ntxhais kawm t-test tau siv los sib piv cov genotypes. *, p < {{20}}.05; **, p <0.01. WT, hom tsiaj qus; KI, thiab GSK3 Ser389 knockin.
2.2. Tsis muaj txiaj ntsig ntawm GSK3 Phosphorylation ntawm Ser389 ntawm Spleen Cells
Txhawm rau tshawb xyuas seb qhov hloov pauv ntawm lub xeev tau kuaj pom hauv GSK3 Ser389 KI nas yog txwv rau lub hlwb lossis seb cov txiaj ntsig puas tseem ua haujlwm, peb tau ua qhov kev ntsuas cytometry rau cov neeg sib txawv ntawm tes hauv tus po. Neutrophils tau txheeb xyuas tias yog Ly6G + hlwb. Ly6G qhia tau txawv txav vim nws nyob ntawm theem loj hlob ntawm cov hlwb, raws li yav dhau los qhia [37]. Tsis tas li ntawd, cov hlwb monocytic myeloid tau sau npe ua Ly6G-CD38+CD11b+ hlwb. Cov monocytes / macrophages tau nthuav tawm ob qho tib si kom meej meej raws li qib ntawm CD38 qhia, raws li tau tshaj tawm yav dhau los [38]. CD8+ hlwb, CD4+ hlwb, thiab B220+ hlwb (B hlwb) kuj raug soj ntsuam (Daim duab S2 hauv Cov Khoom Siv Ntxiv).

Daim duab 2. Kev soj ntsuam Flow cytometry qhia tau hais tias muaj cov kab mob spleen zoo sib xws hauv WT thiab GSK3 Ser389 KI nas. Tom qab kev sib cais ntawm cov hlwb spleen, ntws cytometry tau siv los ntsuas tus naj npawb ntawm (a) Ly6G + neutrophils, (b) CD38+CD11b + monocytes / macrophages, (c) CD4+ hlwb, (d) CD8+ cells, thiab (e) B{10}} cells. Histograms qhia cov xov tooj ntawm tes qhia raws li feem pua ntawm tag nrho cov hlwb. Cov ntaub ntawv sib raug rau qhov txhais tau tias ± SEM (n=5–7). Cov tub ntxhais kawm t-test tau siv los sib piv cov genotypes. WT, hom tsiaj qus; KI, GSK3 Ser389 khob.
2.3. LPS Tsis Muaj Peev Xwm Txhim Kho Neuroinflammation hauv GSK3 Ser389 KI nas
Tom ntej no, peb tshawb xyuas seb puas tshem tawm Ser389 phosphorylation, ntxiv rau qhov ua rau basal tonic o, kuj tuaj yeem cuam tshuam cov lus teb inflammatory tshwm sim los ntawm LPS. WT thiab GSK3 Ser389 KI nas tau txhaj tshuaj intraperitoneally nrog ib koob tshuaj sublethal (0.5 mg/kg) ntawm cov kab mob lipopolysaccharide (LPS). Lub hlwb inflammatory teb tau raug tshuaj xyuas peb hnub tom qab txij li qhov kev kho mob no tau pom yav dhau los ua rau qis qis hauv cov nas hlwb [39,40]. Cov lus teb LPS no kuj zoo ib yam li lub xeev mob ntev uas tau pom nyob rau hauv ntau yam kab mob hauv lub paj hlwb, nrog rau kev nyuaj siab, kev ntxhov siab, thiab tus kab mob Parkinson [41,42]. Raws li xav tau, LPS induced glial reactivity nyob rau hauv WT nas, raws li txiav txim los ntawm qhov nce nyob rau hauv lub zaus ntawm activated microglia/macrophages (Daim duab 3a) thiab tsawg zaus ntawm so microglia (Daim duab 3b). Hauv qhov sib piv, LPS ua tsis tau tejyam ua rau muaj kev cuam tshuam ntxiv hauv GSK3 Ser389 KI nas (Daim duab 3a, b). Table 1 ncaj qha sib piv qhov loj ntawm LPS cov lus teb ntawm ob lub genotypes. Ntxiv rau, qhov kev kho LPS no tau nce feem pua ntawm ACSA-2+ astrocytes hauv WT nas, raws li tau tshaj tawm yav dhau los [31], tab sis tsis nyob hauv GSK3 Ser389 KI nas (Daim duab 3c). Hais txog lub hlwb infiltration ntawm lub cev tiv thaiv kab mob, LPS ua rau muaj kev tsub zuj zuj ntawm neutrophils hauv WT nas tab sis tsis muaj txiaj ntsig hauv GSK3 Ser389 KI nas (Daim duab 3d). Thaum kawg, LPS kev tswj hwm tsis txhawb nqa lymphocyte tsub zuj zuj hauv lub hlwb hauv WT lossis GSK3 Ser389 KI nas (Daim duab 3e). Ua ke, cov kev soj ntsuam no qhia tau hais tias qhov inactivation ntawm GSK3 los ntawm Ser389 phosphorylation yog ib qho tseem ceeb los tiv thaiv ib tug tonic inflammatory xeev nyob rau hauv lub hlwb tab sis ua rau mob hlwb mob nyob rau hauv teb rau stimuli xws li LPS.
Table 1. Qhov txawv ntawm LPS cov teebmeem ntawm WT thiab GSK3 Ser389 KI nas. Cov txiaj ntsig sawv cev ntawm cov xov tooj ntawm tes tom qab kev kho LPS hauv txhua tus genotype thiab qhia tias yog nce ntxiv nrog rau kev tswj xyuas tsheb (txhais tau tias ± SEM). Asterisks qhia qhov sib txawv tseem ceeb ntawm cov teebmeem ntawm LPS hauv WT thiab GSK3 Ser389 KI tsiaj. WT, hom tsiaj qus; KI, GSK3 Ser389 khob; LPS, lipopolysaccharide. *, p < 0 05; **, p <0.01.


Daim duab 3. Neuroimmune hlwb los ntawm GSK3 Ser389 KI nas tsis teb rau LPS. Cov neeg laus WT thiab GSK3 Ser389 KI nas tau txhaj tshuaj intraperitoneally nrog LPS (0.5 mg/kg). Peb hnub tom qab, cov neeg mob hlwb ntawm (a) CD11b++CD45high activated microglia/macrophages, (b) CD11b + CD45low so microglia, (c) ACSA-2+ astrocytes, (d) Ly6G+ neutrophils, thiab ( e) CD11b- lymphocytes raug soj ntsuam los ntawm kev ntws cytometry. Histograms qhia LPS cov teebmeem ntawm cov xov tooj ntawm tes hauv ob qho tib si genotypes. Cov ntaub ntawv raug nthuav tawm raws li feem pua ntawm CD45- hlwb (astrocytes) lossis CD45+ hlwb (tag nrho lwm cov pejxeem), thiab cov txiaj ntsig sib raug rau ± SEM (n=7-9). Cov tub ntxhais kawm t-test tau siv los ntsuas qhov tseem ceeb ntawm kev hloov pauv los ntawm LPS hauv txhua hom kab mob. ** p < 0.01. WT, hom tsiaj qus; KI, GSK3 Ser389 khob; LPS, lipopolysaccharide.
Tom ntej no, peb tshuaj xyuas qhov ua tau ntawm hippocampal GSK3 Ser389 phosphorylation ntawm basal glial activation thiab glial teb rau inflammatory stimuli. Rau lub hom phiaj no, Iba-1 daim ntawv lo tau soj ntsuam los ntawm microscopy hauv dentate gyrus (Daim duab 4a). Ua ntej, WT nas raug soj ntsuam. Micrographs qhia txog kev ua kom qis basal glial, tab sis muaj zog nce hauv glial immunoreactivity hauv kev teb rau LPS txhaj tshuaj (0.5 mg / kg, 3 hnub) (Daim duab 4b). Quantitation ntawm kev sib xyaw ntom ntom rau Iba-1 immunostaining pom qhov tseem ceeb uas yog 53% siab dua hauv WT nas tom qab kho (Daim duab 4d). Cov kev hloov pauv no yog qhov tseem ceeb thiab ua tau raws li qhov tseem ceeb ntawm cellular hypertrophy tshwm sim los ntawm LPS hauv nas hippocampus yav dhau los qhia [43,44].

Daim duab 4. Gliosis teb rau LPS yog hloov pauv hauv GSK3 Ser389 KI nas. Cov neeg laus WT thiab GSK3 Ser389 KI nas tau txhaj tshuaj intraperitoneally nrog LPS lossis tsheb (C). Tom qab 3 hnub, lub paj hlwb tau ua tiav rau fluorescent microscopy. (a) Ib ntu coronal hippocampus yoog los ntawm nas lub hlwb atlas [45] qhia qhov chaw ntawm cov duab, uas suav nrog cov hniav gyrus. (b) Cov ntu hauv hlwb tau txhaj tshuaj tiv thaiv kab mob rau microglia/macrophage cov cim Iba-1. Cov duab qhia txog qhov sib xyaw ua ke ntawm Iba-1 immunoreactivity, uas yog qhov ntsuas ntawm glial reactivity uas qhia txog kev siv zog thiab qhov txuas ntxiv ntawm glial staining. (c) Kev sib piv ntawm kev tswj WT thiab KI tsiaj. (d) LPS teb nyob rau hauv txhua tus nas genotype. Tag nrho cov txiaj ntsig tau nthuav tawm nrog kev hwm rau WT tswj kev kho nrog lub tsheb (txhais tau tias ± SEM, n=4-5). Tub kawm ntawv t-test tau siv. *, p < 0.05. Scale bar, 100 µm. WT, hom tsiaj qus; KI, GSK3 Ser389 khob; C, tsheb; LPS, lipopolysaccharide.
Kev tsom xam ntawm hippocampus ntawm Ser389 KI nas qhia qhov sib txawv ntawm basal microglial activation nrog rau WT nas. Yog li, txawm hais tias kev tshuaj xyuas qhov muag ntawm micrographs tau pom tias muaj kev ua haujlwm nruab nrab ntawm glial hauv cov tsiaj nyeg (Daim duab 4b), kev ntsuas kev sib xyaw ua ke tau qhia tias qhov nce hauv glial immunoreactivity yog qhov tseem ceeb (Daim duab 4c). Interestingly, Ser389 KI nas tsis pom cov tsos mob ntawm kev ua kom muaj zog ntxiv tom qab kev kho LPS (Daim duab 4b), thiab kev soj ntsuam ntau tau lees paub tias LPS tsis tuaj yeem nce Iba-1 kev tiv thaiv kab mob hauv hippocampus (Daim duab 4d), qhia tias glial cell activation los ntawm LPS yog qhov tsis zoo thaum tsis muaj GSK3 Ser389 phosphorylation.

cistanche ntxiv cov txiaj ntsig-Anti-mob
2.5. Peripheral Immune Response rau LPS tsis cuam tshuam rau GSK3 Ser389 KI nas
Peb cov kev sim yav dhau los qhia txog qhov tshwm sim ntawm GSK3 inactivation los ntawm Ser389 phosphorylation ntawm lub hlwb teb rau LPS. Tom ntej no, peb hais seb puas muaj cov teebmeem zoo sib xws hauv kev tiv thaiv kab mob. Txij li thaum LPS paub tias ua rau cov kab mob spleen innate immune cells [46], spleen cell populations los ntawm WT thiab GSK3 Ser389 KI nas raug soj ntsuam 3 hnub tom qab LPS txhaj tshuaj (0.5 mg/kg). tus naj npawb ntawm Ly6G+ neutrophils (Daim duab 5a) thiab CD38++CD11b++Ly6G- monocytes/macrophages (Daim duab 5b) tau nce ntau hauv WT nas hauv kev teb rau LPS kev kho mob. Cov teebmeem LPS no, xav tau hauv WT nas, kuj tau pom hauv GSK3 Ser389 KI nas (Daim duab 5a,b). Tsis muaj qhov sib txawv ntawm cov genotypes tau txais los yog thaum cov neeg lymphocytes los ntawm tus po tau txheeb xyuas, raws li feem pua ntawm spleen CD4+ hlwb (Daim duab 5c) thiab CD8+ hlwb (Daim duab 5d) raug txo los ntawm LPS kuj nyob rau hauv ob leeg nas kab (qhov txo qis hauv cov nas mutant yog qhov tseem ceeb rau CD4+ hlwb); thiab B220+ B hlwb tsis cuam tshuam los ntawm LPS ntawm nws tus kheej ntawm genotype (Daim duab 5e). Cov kev soj ntsuam no yog qhov sib txawv ntawm qhov sib txawv ntawm LPS pom nyob rau hauv lub hlwb ntawm ob lub genotypes. Yog li, thaum GSK3 Ser389 KI nas tiv taus cov kab mob neuroinflammation tshwm sim los ntawm LPS, cov nas no tsis muaj qhov tsis zoo rau LPS. Yog li ntawd, cov teebmeem ntawm GSK3 Ser389 phosphorylation zoo li yuav xaiv rau lub hlwb.

Daim duab 5. Zoo sib xws peripheral immune teb rau LPS hauv GSK3 Ser389 KI thiab WT nas. Cov neeg laus WT thiab GSK3 Ser389 KI nas tau ip txhaj nrog LPS. Tom qab 3 hnub, cov hlwb spleen tau muab rho tawm thiab ua tiav los ntsuas, los ntawm kev ntws cytometry, tus naj npawb ntawm (a) Ly6G + neutrophils, (b) CD38+CD11b + monocytes / macrophages, (c) CD8+, (d) CD4+, thiab (e) B220+ cell. Histograms qhia cov teebmeem ntawm LPS ntawm cov xov tooj ntawm tes, suav nrog WT thiab KI nas. Cov tub ntxhais kawm t-test tau siv los ntsuas qhov tseem ceeb ntawm kev hloov pauv los ntawm LPS hauv txhua hom kab mob. Lub ntsiab lus ± SEM yog qhia (n=5–7). *, p < 0 05; **, p <0.01. WT, hom tsiaj qus; KI, GSK3 Ser389 khob; ip, intraperitoneal; C, tsheb; LPS, lipopolysaccharide.
2.6. LPS-Induced NF-κB Txoj Kev Ua Haujlwm hauv Hippocampus Yog Abolished hauv GSK3 Ser389 KI nas
NF-κB yog qhov tseem ceeb tshaj plaws rau LPS kom ua rau mob [47]. Tsis tas li ntawd, NF-κB tau pom tias tau tswj hwm los ntawm GSK3 hauv lub hlwb [2,19,23]. Peb, yog li ntawd, tau tshuaj xyuas NF-κB ua kom lub hlwb nyob rau hauv cov lus teb rau LPS los ntawm kev tsom xam ntawm IKK phosphorylation, ib kauj ruam thaum ntxov ntawm NF-kB ua kom txoj hauv kev. WT thiab GSK3 Ser389 KI nas tau ip tswj nrog LPS (0.5 mg/kg) thiab tom qab 4 h, hippocampus tau sau. Tag nrho-cell extracts tau siv los tshuaj xyuas phospho-IKK / thiab tag nrho IKK / los ntawm Western blotting. Raws li kev cia siab, LPS nce IKK phosphorylation hauv hippocampus hauv WT nas (Daim duab 6a, b). Nyob rau hauv sib piv, LPS ua tsis tau tejyam induce IKK phosphorylation nyob rau hauv GSK3 Ser389 KI nas (Daim duab 6a, b). Kev ua kom STAT3 kuj tau txuam nrog LPS-induced o [48]. Yog li ntawd peb tau soj ntsuam cov phosphorylation ntawm STAT3 los ntawm Western blot tsom xam. Nyob rau hauv sib piv rau NF-kB ua kom, phosphorylation ntawm STAT3 muaj zog induced nyob rau hauv lub hippocampus ntawm ob WT thiab GSK3 Ser389 KI nas nyob rau hauv teb rau LPS (Daim duab 6a, c). Yog li, tiv thaiv GSK3 inactivation los ntawm Ser389 phosphorylation xaiv impairs NF-κB signaling, uas yog raws li lub luag hauj lwm rau GSK3 raws li ib tug upstream regulator ntawm NF-κB txoj kev nyob rau hauv lub hippocampus. Cov txiaj ntsig no qhia tias GSK3 txoj hauv kev cuam tshuam rau neuroinflammation los ntawm kev tswj cov neeg kho mob tseem ceeb, xws li NF-κB.

Daim duab 6. Kev tsis ua haujlwm GSK3 los ntawm Ser389 phosphorylation sib txawv cuam tshuam rau NF-κB thiab STAT3 signaling hauv LPS-kho nas. Kev ua kom muaj NF-κB thiab STAT3 txoj hauv kev tau kuaj xyuas tag nrho cov cell lysates los ntawm hippocampus 4 h tom qab ip txhaj LPS ({{10}}.5 mg/kg) lossis tsheb (C) hauv ob qho tib si WT thiab GSK3 Ser389 KI nas. Blots qhia txog Western blot tsom xam ntawm phosphor-IKK / , tag nrho IKK / , phosphor-STAT3, thiab tag nrho STAT3. (a) -tubulin kuaj pom tau suav nrog kev tswj kev thauj khoom. Associated graphs sib haum mus rau (b) phospho-IKK / / IKK / thiab (c) phospho-STAT3 / STAT3 ratios, tau los ntawm densitometric tsom xam ntawm Western blot bands. Cov tub ntxhais kawm t-test tau siv los sib piv cov kev tswj tsis tau kho (C) thiab LPS-kho tsiaj hauv txhua hom genotype (txhais tau tias ± SEM, n=5-6). *, p < 0.05; ***, p <0.001. Cov ntaub ntawv yog tus sawv cev ntawm plaub qhov kev sim ywj pheej rau pIKK / IKK thiab peb qhov kev sim ywj pheej rau pSTAT3 / STAT3. WT, hom tsiaj qus; KI, GSK3 Ser389 khob; ip, intraperitoneal; C, tsheb; LPS, lipopolysaccharide.
3. Kev sib tham
Nyob rau hauv lub hlwb, dysregulation ntawm GSK3 kev ua si yog txuas mus rau ntau yam neuropathologies nyob rau hauv uas mob o yog ib tug tshwm sim [25]. Txij li cov ntaub ntawv loj txhawb nqa qhov inhibition ntawm GSK3 los ntawm Ser9 phosphorylation upregulates anti-inflammatory mediators thiab downregulates pro-inflammatory cytokines [23,28,30], cov txheej txheem feem ntau npaj siab los piav qhia txog qhov tsis zoo GSK3 inactivation hauv neuroinflammatory pathologies yog qhov tsis ua hauj lwm rau phosphorylate Ser9 [3]. Txawm li cas los xij, qhov txawv txav tsis zoo ntawm phospho-Ser389 GSK3 tau kuaj pom hauv lub hlwb [4], qhia tias txoj hauv kev no rau GSK3 inactivation kuj tseem ua lub luag haujlwm tseem ceeb hauv lub hlwb. Cov kev sim tau nthuav tawm ntawm no nthuav tawm qhov cuam tshuam ntawm GSK3 Ser389 phosphorylation hauv neuroinflammation, uas ntxiv rau yav dhau los pov thawj qhia txog kev koom tes ntawm txoj hauv kev no hauv hlwb DNA kho thiab neuronal ciaj sia [6,7]. Ib qho ntawm cov kev tshawb pom tseem ceeb hauv txoj haujlwm tam sim no yog tias lub hlwb ntawm GSK3 Ser389 KI nas qhia tau hais tias muaj kev cuam tshuam gliosis thiab nce kev tiv thaiv kab mob hauv lub cev, uas yog raws li kev xav tias tiv thaiv GSK3 inactivation los ntawm Ser389 phosphorylation ua rau neuroinflammation. Cov ntaub ntawv los ntawm peb cov cytometry ndlwg thwmsim qhia kom meej tias yuav nce neuroinflamation nyob rau hauv cov tsiaj no, raws li tus naj npawb ntawm activated microglia/macrophages, ACSA 2+ astrocytes, thiab infiltrated neutrophils nyob rau hauv lub hlwb ntawm Ser389 GSK3 KI nas tau ntau dua. Txawm li cas los xij, txawm hais tias micro-astrogliosis tau pom meej meej los ntawm kev ntws cytometry, kev tsom xam ntawm hippocampus micrographs los ntawm lub paj hlwb ntawm Ser389 GSK3 KI nas qhia tias hypertrophy ntawm microglia / macrophages tsuas yog mob me. Cov txiaj ntsig zoo sib xws tau pom thaum lwm qhov chaw hauv lub hlwb raug tshuaj xyuas los ntsuas qhov ntev thiab qhov hnyav ntawm gliosis (tsis pom). Yog li ntawd, peb txiav txim siab tias, thaum tsis muaj cov stimuli pro-inflammatory, qhov tsis muaj GSK3 Ser389 phosphorylation ua rau ib tug degree ntawm neuroinflammation uas yuav tsum tau muab cais raws li qib qis. Ntau cov kev tshawb fawb txhawb nqa kev koom tes ntawm GSK3 hyperactivity thiab neurodegeneration hauv neurological teeb meem [25]. Hauv cov ntsiab lus no, cov lus teb inflammatory uas peb tau pom hauv Ser389 GSK3 KI nas tuaj yeem yog qhov tshwm sim ntawm neurodegeneration, raws li cov kev tshawb fawb yav dhau los tau kuaj pom kev tuag neuronal hauv cortex thiab hippocampus ntawm cov tsiaj no [6]. Qhov no yog raws li qhov kev soj ntsuam DNA puas inactivates GSK3 los ntawm Ser389 phosphorylation raws li ib tug mechanism los tiv thaiv cell tuag thiab txhawb DSB kho [7,8]. Yog li ntawd, lub hlwb ntawm KI nas, uas Ser389 phosphorylation yog tiv thaiv, tsis tiv thaiv DSB-induced neuronal tuag. Qhov kev sib txuas ntawm phosphor-Ser389 GSK3 qhia thiab cell ciaj sia taus yog thawj zaug hauv cov lymphocytes, raws li ib qho kev cuam tshuam rau hauv lub cev tiv thaiv kab mob. Yog li, qhov tsis muaj GSK3 Ser389 phosphorylation hauv KI nas tau pom los ua rau cov kab mob necroptosis hauv B hlwb thaum nws lig dhau los, uas yog hom mob hnyav heev ntawm cell tuag cuam tshuam nrog ntau yam pathologies [9]. Nws tseem yog qhov nthuav kom nco ntsoov tias tsis yog Ser389 phosphorylation nkaus xwb tab sis kuj Ser9 phosphorylation tuaj yeem ua rau inactivate GSK3 teb rau DNA puas. Txawm li cas los xij, Ser389 GSK3 KI nas tam sim no muaj cov kab mob neurodegenerative phenotype [6] tsis muaj nyob hauv Ser9 GSK3 KI nas [49,50], qhia tias Ser389 phosphorylation plays lub luag haujlwm tshwj xeeb hauv kev tswj hwm ntawm GSK3 kev ua haujlwm thiab muaj cov xwm txheej uas Ser9 phosphorylation tsis tuaj yeem them rov qab. rau qhov poob ntawm Ser389 phosphorylation. Raws li, qhov kev sib txuas zoo ntawm Ser389 GSK3 deregulation, neuroinflammation, thiab neurodegeneration unveiled ntawm no yuav tsum tau tshawb nrhiav ntxiv kom paub meej seb puas hloov GSK3 phosphorylation ntawm Ser389 tej zaum yuav yog ib qho tseem ceeb hauv neuropathologies nyob rau hauv uas mob mob yog txawv, xws li Alzheimer's kab mob. Tsis tas li ntawd, qhov mob me me tab sis pheej ua kom tsis muaj zog ntawm cov hlwb neuroimmune pom hauv GSK3 Ser389 KI nas yog ua raws li qhov kev xav tias tsis ua rau phosphorylate Ser389 tuaj yeem cuam tshuam nrog kev tiv thaiv kab mob. Qhov no yog cov txheej txheem muaj hnub nyoog uas muaj kev poob qis hauv kev tiv thaiv kab mob ua ke nrog kev nce hauv kev qhia ntawm cov neeg kho mob proinflammatory; uas ua rau mob ntev, qis qis [1,51]. Ntau tus kws sau ntawv tau taw qhia txog kev koom tes ntawm GSK3 deregulation hauv hnub nyoog ntsig txog mob [1,52]. Nws kuj tau pom zoo tias qhov kev ua haujlwm tsis zoo ntawm microglia tau pom nyob rau hauv cov ntsiab lus ntawm lub hlwb tiv thaiv kab mob tuaj yeem ua rau neurodegeneration [53]. Yog li, kev tiv thaiv kab mob nrawm nrawm hauv Ser389 GSK3 KI nas tuaj yeem ua rau poob ntawm cov neurons yav dhau los qhia hauv cov tsiaj no [6]. LPS tau siv dav siv los ua kom muaj mob hauv ob qho tib si "hauv vivo" thiab "hauv vitro" qauv. Txawm li cas los xij, muaj pov thawj tias qhov koob tshuaj LPS tau tswj hwm feem ntau txiav txim siab txog hom kev mob tshwm sim tshwm sim [54–56]. Cov koob tshuaj ntau ntawm LPS ua rau cov lus teb septic shocklike; Thaum cov koob tshuaj LPS nruab nrab ua rau muaj qhov mob qis qis qis dua los ze rau qhov pom hauv ntau cov kab mob ntev [42]. Hauv cov ntsiab lus no, nws yog ib qho tseem ceeb uas yuav tsum tau hais tias LPS koob tshuaj tau xaiv rau peb qhov kev sim (0.5 mg / kg, ip) yog nruab nrab thiab nyob deb ntawm LD50 qhia rau LPS hauv cov nas (10-25 mg / kg) [57,58 ]. Hauv kev pom zoo nrog cov ntaub ntawv dhau los [40,59], peb pom tias qhov koob tshuaj LPS no tsis ua rau tuag taus thiab txaus los ua kom gliosis thiab hlwb infiltration ntawm neutrophils hauv WT tsiaj, thaum lymphocyte infiltration tsis cuam tshuam. Remarkably, xws li nruab nrab (tab sis tseem ceeb) LPS cov lus teb tau raug tshem tawm hauv lub hlwb ntawm KI nas nrog kev ua haujlwm tsis zoo ntawm GSK3 los ntawm Ser389 phosphorylation. Raws li qhov kev soj ntsuam no, txuas ntxiv GSK3 hyperactivation nyob rau hauv lub hlwb thaum kawg tuaj yeem txo qis qhov kev xav rau kev ua phem rau kev thuam. Nws yog ib qho tseem ceeb uas cov lus teb tsis zoo rau LPS hauv cov nas mutant yog sib xws nrog cov txheej txheem ntawm kev tiv thaiv kab mob los yog kev tiv thaiv, ib qho txheej txheem hauv CNS tsom los txo qis glial cell activation thiab txwv lub hlwb puas los ntawm kev mob ntau dhau [60,61]. Raws li kev pom zoo nrog lub tswv yim no, kev tshawb fawb yav dhau los tau pom tias GSK3 ua kom cov nas tuaj yeem ua rau muaj kev tiv thaiv kab mob thiab txo qis LPS cov lus teb [62].

Cov txiaj ntsig ntawm cistanche tubulosa- ua kom muaj zog tiv thaiv kab mob
Nws tseem yog qhov nthuav kom xav txog tias cov teebmeem ntawm lub hlwb tau piav qhia hauv qhov kev tshawb fawb no qhia qhov tshwj xeeb. Yog li, tsis sib xws rau lub hlwb, feem ntau cov neeg mob spleen cov neeg soj ntsuam hauv WT thiab Ser389 GSK3 KI tsiaj tau nthuav tawm tib qhov profile hauv cov xwm txheej tsis muaj zog, nrog rau cov lus teb zoo sib xws rau LPS. Qhov no qhia tias GSK3 inactivation txoj kev nyob ntawm Ser389 phosphorylation plays lub luag haujlwm tshwj xeeb hauv kev tswj hwm ntawm neuroinflammation. Raws li kev pom zoo nrog qhov kev xav no, lub hlwb hlwb qhia qhov kev qhia siab ntawm phospho-Ser389 GSK3 piv rau lwm cov ntaub so ntswg, thiab qhov kev qhia no tau nruj tswj hwm thaum lub hlwb loj hlob [5]. Thaum kawg, raws li peb qhov kev tshawb pom, kev tswj hwm ntawm GSK3 los ntawm phosphorylation ntawm Ser389 tshwj xeeb yog kho los ntawm NF-kB kev taw qhia txoj hauv kev, txij li kev ua kom STAT3 tsis cuam tshuam rau Ser389 GSK3 KI. Ntau tus neeg nruab nrab hauv nruab nrab yog tswj hwm los ntawm NF-kB ua kom muaj zog, suav nrog cytokines, receptors, transcription yam, thiab enzymes. Kev txheeb xyuas qhov twg ntawm cov hom phiaj NF-kB no cuam tshuam los ntawm Ser389 GSK3 phosphorylation yog dhau ntawm peb txoj haujlwm, tab sis nws yuav yog lub hom phiaj zoo siab rau cov kev tshawb fawb yav tom ntej txhawm rau qhia meej txog cov txheej txheem ntawm neuroinflammation.
4. Cov ntaub ntawv thiab cov txheej txheem
4.1. Tsiaj txhu
C57BL/6J Cov nas qus (WT) tau yuav los ntawm Jackson Laboratories. C57BL/6 GSK3 Ser389 KI nas, nyob rau hauv uas Ser389 residue ntawm GSK3 tau hloov los ntawm Ala los tiv thaiv phosphorylation, tau tsim raws li yav tas los piav [8]. Txhua tus nas tau nyob hauv thaj chaw tsiaj cuam tshuam nrog Albacete Medical School nyob rau hauv 12- lub voj voog teeb / tsaus. Khoom noj thiab dej tau muab rau libitum. Cov nas muaj hnub nyoog plaub mus rau rau lub hlis tau siv rau kev sim.
4.2. LPS Administration
Txhawm rau ua kom muaj cov lus teb inflammatory, nas tau txais ib qho tshuaj intraperitoneal (ip) ntawm {{0}}.5 mg/kg LPS. Salmonella enterica LPS (serotype typhimurium, L7261 Sigma Aldrich, Madrid, Spain) tau yaj hauv sterile, endotoxin-dawb 0.9% saline ntawm 10 mg/mL. Peb hnub tom qab kev kho mob, nas tau euthanized, thiab lub hlwb thiab tus po tau raug tshem tawm rau immunohistochemistry los yog ntws cytometry tsom xam ntawm glial hlwb thiab infiltrated lub cev tiv thaiv kab mob. Rau Western blotting tsom xam, tsiaj tau euthanized 4 h tom qab ip txhaj ntawm 0.5 mg / kg LPS, raws li yav tas los LPS tau tshaj tawm los upregulate inflammatory proteins nyob rau hauv nas thiab nas hlwb 2-4 h tom qab ip tswj [63,64].
4.3. Flow Cytometry
Rau cov cytometry flow cytometry ntawm lub hlwb cov ntaub so ntswg thiab spleen hlwb, tsiaj tau tshuaj loog nrog ib tug ip txhaj ntawm tribromoethanol, uas tau pom zoo rau cov kev tshawb fawb terminal mob. Cov koob tshuaj tsawg tsawg ntawm tribromoethanol siv (200 mg / kg) muab tshuaj loog tsis muaj teebmeem loj lossis cuam tshuam rau inflammatory cytokine qhia [65]. Tsiaj cov txheej txheem tau ua tom qab kuaj xyuas qhov tsis muaj reflexes.
4.3.1. Brain Tissue Dissociation thiab Percoll Gradient Isolation ntawm Neural Cells
Cov nas tsuag tau intracardially perfused nrog 50 mL ntawm 0.9% NaCl ua ntej sau cov ntaub so ntswg kom tshem tawm cov hlwb los ntawm cov hlab ntsha hlwb. Tom qab perfusion, lub hlwb raug tshem tawm, meninges thiab choroid plexus tau ua tib zoo sib cais, thiab lub cerebellum thiab olfactory qij raug muab pov tseg. Cov ntaub so ntswg ntxiv tau muab tso rau hauv txias Hank's Balanced Salt Solution, uas yog calcium chloride thiab magnesium chloride dawb (HBSS [-]CaCl2 / [-]MgCl2: Gibco, Madrid, Spain, 14175). Cov ntaub so ntswg tom qab ntawd finely tws nrog ib tug scalpel ua ntej digestion. Tom qab ntawd cov ntaub so ntswg txiav tau muab tso rau hauv MACS C hlab (Miltenyi Biotec, Pozuelo de Alarcón, Spain, 130-093-237) hauv tag nrho cov ntim ntawm 5 mL, thiab ua tiav nrog tus kws kho tshuab dissociator ntawm 6 rpm rau 30 min. Enzymatic dissociation tau ua raws li peb tus kheej raws tu qauv [31] siv papain (100 U; Worthington, LK003178) thiab dispase II (6 U; Sigma-Aldrich, Madrid, Spain, D4963) hauv Earle's Balanced Salt Solution (EBSS [+]CaCl2 /[+]MgSO4; Gibco, Madrid, Spain, 24010). DNAse I (100 U; Sigma-Aldrich, Madrid, Spain, DN25) tau ntxiv rau kev daws kom tshem tawm cov kab mob DNA uas cuam tshuam rau cell viability [66]. Ua ntej siv, papain tau qhib rau 30 feeb ntawm 37 ◦C hauv 5% CO2. Txhawm rau tiv thaiv kev zom zaub mov, cov qauv tau diluted nrog HBSS txias thiab muab tso rau hauv dej khov. Cov tshuaj no tau muab tso rau hauv 10 zaus siv 5 mL pipettes thiab lim los ntawm 70 µm cell strainer (BD, 352350). Qhov tshwm sim ib leeg-cell raug tshem tawm yog centrifuged ntawm 300 × g rau 10 min ntawm RT. Ib 30% PercollTM (GE Healthcare, Madrid, Spain, 17-0891-01) gradient tau siv los tshem tawm cov myelin thiab txhawb cov homogenate rau hauv cov hlwb glial. Rau lub hom phiaj no, ib qho kev daws teeb meem ntawm isotonic Percoll (SIP) tau npaj (9: 1 Percoll hauv 10 × HBSS [-]CaCl2 / [-]MgCl2; Gibco, 14185), thiab cell pellets tau rov ua dua hauv 30% (v / v) SIP (hauv 1 × HBSS). Qhov 30% Percoll gradient tau ua los ntawm kev ntxiv 3 mL ntawm SIP rau 7 mL ntawm 1 × HBSS uas muaj cov xov tooj ntawm tes ncua hauv 14 mL polypropylene raj. Txhua qhov gradient tau centrifuged yam tsis muaj nres ntawm 300 × g rau 30 min ntawm 18 ◦C. Tom qab centrifugation, cov hlwb los ntawm cov txheej hauv qab tau sau, ntxuav nrog 1 × HBSS, centrifugated rau 10 min ntawm 300 × g, thiab resuspended nyob rau hauv 10 mL ntawm 1 × cov ntshav liab lysis tsis nyob ntawm 4 ◦C. Tom qab lysis, cell ncua kev kawm ntawv yog centrifuged ntawm 300 × g rau 10 min, thiab cov resulting cell pellet thaum kawg resuspended nyob rau hauv 50 µL ntawm thaiv tsis pub ua ntej staining rau ntws cytometry.
4.3.2. Spleen Cell Dissociation
Spleens tau muab tso rau ntawm Petri tais uas muaj RPMI 1640 thiab txiav rau hauv me me. Cov ntaub so ntswg tshwm sim tau dhau mus rau hauv 70 µm cell strainer (BD, 352350) thiab tawg tuaj rau hauv ib lub voj voog nrog lub ribbed sab saum toj ntawm lub koob txhaj tshuaj lub plunger. RPMI 1640 tom qab ntawd dhau los ntawm cov lim dej. Cov ntaub so ntswg disintegrated tau pauv mus rau 50 mL hlab (Sarstedt, Barcelona, Spain, 62.547.254) thiab centrifuged ntawm 100 g rau 10 min. Tom qab ntawd cov supernatant uas muaj cov xov tooj ntawm tes raug tshem tawm thiab muab centrifuged dua ntawm 300 g rau 10 min. Qhov tshwm sim supernatant raug tshem tawm, thiab cov pellet tau rov ua dua nyob rau hauv 10 mL phosphate-buffered saline (PBS) nrog 1% FBS los suav cov xov tooj hauv qab lub tshuab tsom, tom qab ntawd nws tau rov centrifuged ntawm 300 g rau 5 min. Tsuas yog 500,{19}} cov cell rau ib qho qauv tau siv. Txhua tus qauv tau rov ua dua nyob rau hauv 50 µL ntawm kev thaiv tsis pub ua ntej staining rau ntws cytometry.
4.3.3. Extracellular Flow Cytometry Staining
Table 2. Cov tshuaj tiv thaiv kab mob thiab cov tshuaj reagents siv rau kev ntsuas cytometry.

4.4. Immunohistochemistry
Cov nas tau txhaj tshuaj loog thiab intracardially perfused nrog saline {{0}}.9% (w/v). Lawv lub hlwb tau sau thiab kho tom qab kho nrog 4% paraformaldehyde rau 24 teev. Tom qab kev txhim kho tom qab, lawv tau tiv thaiv kev tiv thaiv nrog 30% sucrose thiab khov ntawm −20 ◦C kom txog rau thaum muab faib. Cov ntaub so ntswg (20 µm) raug txiav siv lub cryostat (ThermoFisher, Microm™ HM550), thaw mounted rau Superfrost Plus slides (ThermoFisher, J1800AMNZ) thiab thaum kawg khaws cia ntawm −20 ◦C kom txog thaum staining. Immunohistochemical staining ntawm cov ntaub so ntswg tau ua raws li tau piav qhia ua ntej [67]. Cov tshuaj tiv thaiv thawj thiab theem nrab tau diluted hauv 1 × PBS nrog 1% BSA. Cov seem tau tsim nrog thawj cov tshuaj tiv thaiv kab mob tiv thaiv luav Iba-1 (1:500 dilution; Wako Chemicals, Barcelona, Spain, 019-19741). Alexa Fluor 488-conjugated tshis tiv thaiv luav IgG (1: 2000 dilution; ThermoFisher, Madrid, Spain, A11031) tau siv los ua cov tshuaj tiv thaiv thib ob. Tsim nyog cov ntaub so ntswg tswj tau zoo, nrog rau cov thawj thiab theem nrab tswj tsis zoo. Fluorescent labeling dluab tau txais los ntawm ZEISS Apotome. 2 microscope nrog axiom 503 mono digital lub koob yees duab thiab Zen Blue tswj software version 2.3 (Carl Zeiss). Lub hom phiaj 10 × (Plan-APOCHROMAT, V10 ×, NA 0.45, AIR) tau siv los ua kom pom lub hippocampus. Qhov sib xyaw ua ke ntom ntom hauv thaj tsam ntawm kev txaus siab tau suav nrog ImageJ software. Qhov kev ntsuas no sib raug rau cov lej ntawm qhov kev siv zog rau txhua pixel hauv cheeb tsam xaiv. Yog li ntawd, nws yog siv rau kom muaj nuj nqis ntawm cov xov tooj ntawm tes stained nyob rau hauv ua ke nrog nrog rau staining siv ntawm txhua cell.

cistanche tubulosa- txhim kho lub cev tiv thaiv kab mob
4.5. Western Blot Analysis
Cov nas hlwb raug tshem tawm sai sai, thiab cov hippocampi tau muab tshem tawm tam sim ntawd thiab khov. Cov ntaub so ntswg tau npaj siv lub hypertonic lysis tsis muaj cov protease inhibitors raws li tau piav qhia yav dhau los [68]. Thawj cov tshuaj tiv thaiv siv tau los tiv thaiv luav phosphor-IKK / (1: 1000 dilution; Cell Signaling, Alcobendas, Spain, 2861), anti-luv IKK / (1: 1000 dilution; Santa Cruz Biotechnology, Heidelberg, Lub teb chaws Yelemees, sc{{ 9}}), antirabbit phosphor-STAT3 (1: 1000 dilution; Cell Signaling, 9145) thiab anti-nas STAT3 (1: 1000 dilution; Santa Cruz Biotechnology, sc-8019). Anti-nas -tubulin (1: 2000 dilution; Santa Cruz Biotechnology, sc{24}}) tau siv los ua kev tswj kev thauj khoom. Anti-Lavbit HRP (1: 5000 dilution; Jackson ImmunoResearch Laboratories, Baltimore, USA, 111-035-144) thiab anti-nas HRP (1: 5000 dilution; Jackson ImmunoResearch Laboratories, 115-035-003) tau siv los ua cov tshuaj tiv thaiv kab mob thib ob . Protein band quantification yog ua los ntawm band densitometry tsom xam nrog NIH ImageJ Software (Version 1.50i, https://imagej.nih.gov/ij/, nkag rau 1 Lub Peb Hlis 2022). Txhawm rau kom muaj kev sib npaug sib npaug, qhov sib xyaw ua ke tau txais los ntawm txhua pawg tau nthuav tawm raws li tus nqi txheeb ze nrog rau kev tswj xyuas cov khoom tu vaj tse tsim nyog.
4.6. Kev txheeb cais
Cov txiaj ntsig tau raug txheeb xyuas nrog GraphPad Prism software (San Diego, CA, USA). Cov ntaub ntawv raug nthuav tawm raws li qhov txhais tau tias ± tus qauv yuam kev ntawm qhov nruab nrab (SEM) ntawm feem ntau plaub qhov kev sim ywj pheej (n {{0}}-9). Tom qab lees paub qhov kev faib tawm ib txwm muaj los ntawm kev xeem Shapiro-Wilk, qhov tseem ceeb ntawm ob pawg tau txiav txim siab los ntawm Tub Ntxhais Kawm t-test rau cov ntaub ntawv parametric. Qhov sib txawv tau suav tias yog qhov tseem ceeb tshaj plaws thaum qhov tshwm sim (p) qhov tseem ceeb tsawg dua 0.05 (*), 0.01 (**), lossis 0.001 (***). Cov duab qhia cov neeg sawv cev kev sim.
5. Cov lus xaus
Hauv cov ntsiab lus, peb cov kev tshawb pom qhia tias tsis ua haujlwm GSK3 los ntawm Ser389 phosphorylation ua rau mob ntev thiab endotoxin kam rau ua thiab qhov inhibition ntawm GSK3 los ntawm Ser9 thiab Ser389 phosphorylation plays complementary thiab tsis redundant luag hauj lwm nyob rau hauv lub neuroimmune teb. Yog li, cov txiaj ntsig tshwj xeeb ntawm GSK3 Ser389 phosphorylation rau neuropathology thiab hlwb laus yuav tsum tau tshawb xyuas.
Cov ntaub ntawv
1. Souder, DC; Anderson, RM Ib qho kev nthuav dav GSK3 network: Qhov cuam tshuam rau kev tshawb fawb kev laus. Geroscience 2019, 41, 369–382. [CrossRef] [PubMed]
2. Hoeflich, KP; Luo, J.; Rubie, EA; Tsao, M.; Jin, O.; Woodgett, JR Requirement for glycogen synthase kinase-3 hauv cell survival thiab NF-κB ua kom. Xwm 2000, 406, 86–90. [CrossRef] [PubMed]
3. Yob, RS; Johnson, GV Lub glamour thiab gloom ntawm glycogen synthase kinase -3. Trends Biochem. Sci. 2004, 29, 95–102. [CrossRef]
4. Thornton, TM; Pedraza-Alva, G.; Deng, IB; Ntoo, CD; Aronshtam, UA; Clements, JL; Sabio, G.; Davis, RJ; Matthews, DE; Daws, B.; ua al. Phosphorylation los ntawm p38 MAPK ua lwm txoj hauv kev rau GSK3beta inactivation. Science 2008, 320, 667–670. [CrossRef]
5. Calvo, IB; Thornton, TM; Rincon, M.; ib. Tranque, P.; Fernandez, M. Kev tswj hwm ntawm GSK3 los ntawm Ser 389 Phosphorylation Thaum Lub Sijhawm Neural Development. Mol. Neurobiol. Xyoo 2020, 58, 809–820. [CrossRef] [PubMed]
6. Thornton, TM; Hlo, B.; Coli, S.; Pendlebury, WW; Neeb, AR; Foob, W.; Jaworski, DM; Rincon, M. Kev tsis ua haujlwm Nuclear GSK3 los ntawm Ser 389-Phosphorylation Ua rau Focal Neuronal Tuag thiab Kev Ntshai Ntshai ntev. Neuropsychopharmacology 2018, 43, 393–405. [CrossRef] [PubMed]
7. Hlo, BD; Thornton, TM; Rincon, M.; ib. Golijanin, IB; King, SB; Jaworski, DM; Caij nplooj zeeg, WA Ob lub lis piam ntawm kev ntxhov siab hloov pauv nce qib gamma-H2AX hauv nas txaj nucleus ntawm stria terminalis. Neuroscience 2018, 373, 137–144. [CrossRef]
8. Thornton, TM; Delgado, P. Chen, L.; Salas, IB; Krementsov, D.; Fernandez, M.; ib. Vernia, S.; Davis, RJ; Heiman, R.; Teuscher, C.; ua al. Inactivation ntawm nuclear GSK3beta los ntawm Ser (389) phosphorylation txhawb nqa lymphocyte zog thaum DNA ob-strand so teb. Nat. Pawg. 2016, 7, 10553. [CrossRef]
9. Pasparakis, M.; Vandenabeele, P. Necroptosis thiab nws lub luag haujlwm hauv o. Xwm Txheej 2015, 517, 311–320. [CrossRef]
10. Jope, RS; Cheng, Y.; Lowell, JA; Tsim nyog, RJ; Sibbon, YH; Beurel, E. Stressed thiab Inflamed, GSK3 puas tuaj yeem liam? Trends Biochem. Sci. 2017, 42, 180–192. [CrossRef]
11. Beutler, IB; Rietschel, ET Innate immune sensing, thiab nws cov hauv paus hniav: Zaj dab neeg ntawm endotoxin. Nat. Rev. Immunol. 2003, 3, 169–176. [CrossRef] [PubMed]
12. Morris, MC; Gilliam, EA; Khawm, J.; Li, L. Dynamic modulation of innate immune teb los ntawm kev sib txawv ntau npaum lipopolysaccharide (LPS) hauv tib neeg monocytic hlwb. J. Biol. Chem. 2014, 289, 21584–21590. [CrossRef]
13. Lu, YC; Yees, WC; Ohashi, PS LPS / TLR4 teeb liab hloov txoj kev. Cytokine 2008, 42, 145–151. [CrossRef] [PubMed]
14. Ko, R.; Yaj, HD; Lee, SY GSK3 inhibitor peptide tiv thaiv nas los ntawm LPS-induced endotoxin shock. Immune Netw. 2010, 10, 99. [CrossRef] [PubMed]
15. Piazzi, M.; Bavelloni, A.; Cenni, V.; Faenza, ib.; Blalock, WL Revisiting the Role of GSK3, Tus Modulator ntawm Innate Immunity, hauv Idiopathic Inclusion Body Myositis. Cells 2021, 10, 3255. [CrossRef] [PubMed]
16. Neeb, A.; Cai, S.; Goldberg, ib.; Saxena, UA; Pillarisetti, S. Novel anti-inflammatory luag hauj lwm rau glycogen synthase kinase -3beta nyob rau hauv inhibition ntawm qog necrosis factor-alpha- thiab interleukin -1beta-induced inflammatory gene qhia. J. Biol. Chem. 2006, 281, 16985–16990. [CrossRef]
17. Hoffmeister, L.; Diekmann, M.; Hom, K.; Huber, R. GSK3: Ib qho Kinase Ntsuas Kev Tshaj Tawm thiab Kev daws teeb meem ntawm qhov mob. Cells 2020, 9, 820. [CrossRef]
18. Beurel, E.; Jope, RS Lipopolysaccharide-induced interleukin -6 ntau lawm yog tswj los ntawm glycogen synthase kinase-3 thiab STAT3 hauv lub hlwb. J. Neuroinflamm. 2009, 6, 9. [CrossRef]
19. Vaj, M.; Huang, H.; Chen, W. Chang, H.; Kuo, J. Glycogen synthase kinase-3 inactivation inhibits qog necrosis factor-production hauv microglia los ntawm modulating nuclear factor κB thiab MLK3/JNK signaling cascades. J. Neuroinflamm. 2010, 7, 99. [CrossRef]
20. Priego, N.; Valiente, M. Lub peev xwm ntawm astrocytes raws li kev tiv thaiv kab mob hauv cov qog hlwb. Pem hauv ntej. Immunol. 2019, 10, 1314. [CrossRef]
21. Vandenbark, AA; Offner, H.; Matejuk, S.; Matejuk, A. Microglia thiab astrocyte kev koom tes hauv neurodegeneration thiab mob qog noj ntshav hauv hlwb. J. Neuroinflamm. 2021, 18, 298. [CrossRef] [PubMed]
22. Lucas, JJ; Hernandez, F.; ib. Gomez-Ramos, P.; Moran, MA; Hen, R.; Avila, J. Txo nuclear beta-catenin, tau hyperphosphory lation, thiab neurodegeneration hauv GSK-3beta conditional transgenic nas. EMBO J. 2001, 20, 27–39. [CrossRef] [PubMed]
23. Jorge-Torres, OC; Szczesna, K.; Rau, L.; Casal, C.; Gonzalez-Somermeyer, L. Soler, M.; Velasco, CD; Martinez-San Segundo, P.; Petas, P.; Saez, MA; ua al. Inhibition ntawm Gsk3b Txo Nfkb1 Kev Tshaj Tawm thiab cawm Synaptic Activity los txhim kho Rett Syndrome Phenotype hauv Mecp2-Knockout nas. Cell. Rep. 2018, 23, 1665–1677. [CrossRef] [PubMed]
24. Martin, M.; Rehani, K.; Yog, RS; Michalek, SM Toll-like receptor-mediated cytokine ntau lawm yog sib txawv tswj los ntawm glycogen synthase kinase. Nat. Immunol. 2005, 6, 777–784. [CrossRef]
25. Rippin, ib.; Eldar-Finkelman, H. Mechanisms and therapeutic implications of GSK-3 hauv kev kho mob neurodegeneration. Cells 2021, 10, 262. [CrossRef]
26. Androulidaki, A.; Iliopoulos, D.; Arranz, UA; Doxaki, C.; Schworer, S.; Zacharioudaki, V.; Margioris, AN; Tsichlis, PN; Tsatsanis, C. Lub kinase Akt1 tswj macrophage teb rau lipopolysaccharide los ntawm kev tswj hwm microRNAs. Kev tiv thaiv kab mob 2009, 31, 220–231. [CrossRef]
27. Fichtner-Feigl, S.; Keselring, R.; Martin, M.; ib. Obermeier, F.; Ruemmel, P.; Kitani, A.; Brunner, SM; Hais, M.; Geissler, EK; Strober, W. IL-13 orchestrates kev daws teeb meem ntawm kev mob plab hnyuv ntawm phosphorylation ntawm glycogen synthase kinase -3 . J. Immunol. 2014, 192, 3969–3980. [CrossRef]
28. Nagao, M.; Hayashi, H. Glycogen synthase kinase-3beta yog txuam nrog Parkinson's disease. Neurosci. Lett. 2009, 449, 103–107. [CrossRef]
29. Nadri, C.; Kozlovsky, N.; Agam, G.; Bersudsky, Y. GSK-3 tsis nyob hauv lymphocytes ntawm cov neeg mob schizophrenic. Psychiatry Res. 2002, 112, 51–57. [CrossRef]
30. Jope, RS; Yuskaitis, CJ; Beurel, E. Glycogen synthase kinase-3 (GSK3): Kab mob, kab mob, thiab kev kho mob. Neurochem. Res. 2007, 32, 577–595. [CrossRef]
31. Calvo, B.; Rubio, F.; Fernández, M. Tranque, P. Dissociation ntawm neonatal thiab neeg laus nas lub hlwb rau ib txhij tsom xam ntawm microglia, astrocytes thiab infiltrating lymphocytes los ntawm ntws cytometry. IBRO Rep. 2020, 8, 36–47. [CrossRef] [PubMed]
32. Legroux, L.; Pitt, CL; Beauseigle, D.; Deblois, G.; Prat, A.; Arbour, N. Ib txoj hauv kev zoo los ua cov nas CNS rau ib txhij soj ntsuam cov hlwb neural thiab leukocytes los ntawm ntws cytometry. J. Neeb. Txoj Kev 2015, 247, 23–31. [CrossRef] [PubMed]
33. Batiuk, KUV; de Vin, F.; Duque, SI; Li, C.; Saito, T.; Saido, T.; Fias, M.; Belgard, TG; Holt. J. Biol. Chem. Xyoo 2017, 292, 8874–8891. [CrossRef] [PubMed]
34. Stevens, SL; Bao, J.; Hollis, J.; Lesov, NS; Clark, WM; Stenzel-Poore, MP Kev siv cov cytometry ntws los ntsuas kev hloov pauv ntawm lub cev hauv cov hlwb tom qab focal cerebral ischemia hauv cov nas. Lub hlwb Res. 2002, 932, 110–119. [CrossRef] [PubMed]
35. Kantzer, CG; Boutin, C.; ib. Herzig, ID; Wittwer, C.; Reis, S.; Tiveron, MC; Drewes, J.; Rockel, TD; Ohlig, S.; Ninkovic, J.; ua al. Anti-ACSA-2 txhais cov tshuaj tiv thaiv monoclonal tshiab rau yav tom ntej kev cais tawm ntawm cov menyuam yaus thiab cov neeg laus astrocytes. Glia 2017, 65, 990–1004. [CrossRef]
36. Moreno-García, Á.; Bernal-Chico, UA; Colomer, T.; Rodríguez-Antigüedad, A.; Muas, C.; Mato, S. Gene qhia kev tsom xam ntawm astrocyte thiab microglia endocannabinoid signaling thaum lub sij hawm autoimmune demyelination. Biomolecules 2020, 10, 1228. [CrossRef] [PubMed]
37. Deniset, JF; Surewaard, BG; Li, W.; Kubes, P. Splenic Ly6Ghigh mature thiab Ly6Gint tsis paub qab hau neutrophils pab rau kev tshem tawm ntawm S. pneumoniae. J. Exp. Med. 2017, 214, 1333–1350. [CrossRef]
38. Ng, HHM; Li, RY; Goh, S.; Tias, ISY; Lim, X.; Li, B.; Chaw, V.; Li, H.; Tan, B.; Lim, S.; ua al. Immunohistochemical scoring ntawm CD38 nyob rau hauv cov qog microenvironment kwv yees ua teb rau anti-PD-1/PD-L1 immunotherapy nyob rau hauv hepatocellular carcinoma. J. Immunother. Cancer 2020, 8, e000987. [CrossRef]
39. Okuyama, S.; Makhihata, N.; Yoshimura, M. Asakura, Y.; Yoshida, T.; Nakajima, M.; Furukawa, Y. Oenothein B suppresses lipopolysaccharide (LPS)-induced o nyob rau hauv nas hlwb. Int. J. Mol. Sci. Xyoo 2013, 14, 9767–9778. [CrossRef]
40. Carnevale, D.; Mascio, G.; Ajmone-Cat, MA; D'Andrea, ib.; Cifelli, G.; Madonna, M.; Cocozza, G.; Frati, A.; Carullo, P. Carnevale, L.; ib. ua al. Lub luag hauj lwm ntawm neuroinflamation nyob rau hauv hypertension-induced hlwb amyloid pathology. Neurobiol. Hnub nyoog 2012, 33, e19–e205. [CrossRef]
41. Zhang, J.; Xu, B.; Jing, IB; Tian, H.; Zhang, N.; Li, M.; Lus, L.; Chen, L.; Diao, H.; Chen, Y. LPS activates neuroinflammatory pathways induce depression in Parkinson's disease-zoo li tus mob. Pem hauv ntej. Pharmacol. 2022, 13, 961817. [CrossRef] [PubMed] 4
2. Tarr, AJ; Chen, Q.; Wang, Y.; Sheridan, JF; Quan, N. Neural thiab kev coj cwj pwm teb rau cov qib qis. Behav. Lub hlwb Res. 2012, 235, 334–341. [CrossRef] [PubMed]
43. Kang, J.; Park, D.; Shah, M.; Kim, M.; Koh, P. Lipopolysaccharide induces neuroglia activation thiab NF-κB activation nyob rau hauv cerebral cortex ntawm cov laus nas. Lab. Anim. Res. 2019, 35, 19. [CrossRef]
44. Khan, MS; Ali, T.; Abid, MN; Yog, MH; Khan, UA; Kim, MW; Yoon, GH; Cheon, EW; Rehman, UAS; Kim, MO Lithium ameliorates lipopolysaccharide-induced neurotoxicity nyob rau hauv lub cortex thiab hippocampus ntawm cov laus nas hlwb. Neurochem. Int. 2017, 108, 343–354. [CrossRef] [PubMed]
45. Paxinos, G.; Franklin, KB nas hlwb hauv Stereotaxic Coordinates. 2001. Muaj nyob online: https://books.google.es/books/ about/The_Mouse_Brain_in_Stereotaxic_Coordinat .html?id=tZdjQgAACAAJ&redir_esc=y (accessed on 1 March 2022).
46. Bronte, V.; Pittet, MJ Tus spleen hauv zos thiab kev tswj hwm kev tiv thaiv kab mob. Kev tiv thaiv 2013, 39, 806–818. [CrossRef]
47. Liu, T.; Zhang, L. Yog, D.; Sun, S. NF-κB signaling in o. Teeb liab Transduct. Hom phiaj. Ther. 2017, 2, 17023. [CrossRef] [PubMed]
48. Balic, JJ; Albargy, H.; Lus, K.; Kirby, FJ; Jayasekara, NWS; Mansell, F.; Garama, DJ; De Nardo, D.; Baschuk, N.; Louis, C. STAT3 serine phosphorylation yog xav tau rau TLR4 metabolic reprogramming thiab IL-1 qhia. Nat. Pawg. 2020, 11, 3816. [CrossRef]
49. Hongisto, V.; Vainio, JC; Thompson, R.; Courtney, MJ; Coffey, ET Lub pas dej Wnt ntawm glycogen synthase kinase 3beta yog qhov tseem ceeb rau trophic-deprivation-induced neuronal tuag. Mol. Cell. Biol. 2008, 28, 1515–1527. [CrossRef]
50. Eom, T.; Jope, RS Blocked inhibitory serine-phosphorylation ntawm glycogen synthase kinase -3 / impairs hauv vivo neural precursor cell proliferation. Biol. Psychiatry 2009, 66, 494–502. [CrossRef] 5
1. Franceschi, C.; Campisi, J. Chronic o (mob) thiab nws cov peev xwm pab tau rau cov kab mob uas muaj hnub nyoog. J. Gerontol. Ser. Ib Biomed. Sci. Med. Sci. 2014, 69, S4–S9. [CrossRef]
52. Enioutina, EY; Bareyan, D.; Daynes, RA Lub luag haujlwm rau cov hlwb tsis paub qab hau hauv lub cev tsis muaj zog. J. Immunol. 2011, 186, 697–707. [CrossRef] [PubMed]
53. Tang, Y.; Le, W. Kev sib txawv ntawm M1 thiab M2 microglia hauv cov kab mob neurodegenerative. Mol. Neurobiol. 2016, 53, 1181–1194. [CrossRef] [PubMed]
54. Hoogland, IC; Houbolt, C.; van Westerloo, DJ; van Gool, WA; van de Beek, D. Systemic o thiab microglial activation: Systematic review of animal trials. J. Neuroinflamm. 2015, 12, 114. [CrossRef] [PubMed]
55. Furube, E.; Cai, S.; Inagaki, H.; Takagi, S.; Miyata, S. Brain Region-dependent Heterogeneity thiab Dose-dependent Difference nyob rau hauv Transient Microglia Population nce thaum lub sij hawm lipopolysaccharide inflamation. Sci. Rep. 2018, 8, 2203. [CrossRef]
56. Brandi, E.; Torres-Garcia, L.; Svanbergsson, UA; Hais, C.; Liu, D.; Li, W.; Li, J. Brain cheeb tsam tshwj xeeb microglial thiab astrocytic activation nyob rau hauv teb rau systemic lipopolysaccharides raug. Pem hauv ntej. Kev laus Neurosci. 2022, 14, 910988. [CrossRef]
57. Radulovic, K.; Mak'Anyengo, R.; Cai, B.; Steinert, UA; Niess, JH Txhaj tshuaj lipopolysaccharide rau hauv nas kom ua raws li kev nkag ntawm microbial-derived khoom tom qab plab hnyuv ua txhaum cai. J. Vis. Exp. Xyoo 2018, 135, e57610. [CrossRef]
58. Fink, MP Tsiaj qauv ntawm sepsis. Virulence 2014, 5, 143–153. [CrossRef]
59. Zhou, H.; Andonegui, G.; Wong, CH; Kubes, P. Lub luag hauj lwm ntawm endothelial TLR4 rau neutrophil recruitment rau hauv nruab nrab paj hlwb microvessels nyob rau hauv lub cev o. J. Immunol. 2009, 183, 5244–5250. [CrossRef]
60. Beurel, E. HDAC6 tswj LPS-tolerance hauv astrocytes. PLoS IB 2011, 6, e25804. [CrossRef]
61. Yao, L.; Li, P. Chen, Q.; Hu, A.; Wu, Y.; Li, B. Kev tiv thaiv los ntawm endotoxin kam rau ua rau peripheral lipopolysaccharide-induced neuroinflammation thiab dopaminergic neuronal raug mob. Immunopharmacol. Immunotoxicol. 2022, 44, 326–337. [CrossRef] 62. Park, SH; Park-Min, KH; Chen, J.; Hu, X.; Ivashkiv, LB Tumor necrosis factor induces GSK3 kinase-mediated cross-tolerance to endotoxin in macrophages. Nat. Immunol. 2011, 12, 607–615. [CrossRef] [PubMed]
63. Yamawaki, Y.; Shirawachi, S.; Mizokami, A.; Nozaki, K.; Ib, H.; Asano, S.; Aw, K.; Aizawa, H.; Yamawaki, S.; Hirata, M. Phospholipase C-txog catalytically inactive protein regulates lipopolysaccharide-induced hypothalamic o mob kho anorexia nyob rau hauv nas. Neurochem. Int. 2019, 131, 104563. [CrossRef] [PubMed]
64. Shah, SA; Khan, M.; Yog, M.; Yog, MG; Amin, FU; Kim, MO Melatonin txhawb nqa SIRT 1 / Nrf2 signaling pathway counteracting lipopolysaccharide (LPS)-induced oxidative stress to save postnatal nas brain. CNS Neurosci. Ther. Xyoo 2017, 23, 33–44. [CrossRef] [PubMed]
65. Cho, YJ; Li, YA; Li, JW; Kim, JI; Han, JS Kinetics ntawm proinflammatory cytokines tom qab intraperitoneal txhaj ntawm tribromoethanol thiab tribromoethanol / xylazine ua ke hauv ICR nas. Lab. Anim. Res. 2011, 27, 197–203. [CrossRef] [PubMed]
66. Posel, C.; Moller, K.; Bolts, J.; Wagner, DC; Weise, G. Isolation and Flow Cytometric Analysis of Immune Cells from the Ischemic Mouse Brain. J. Vis. Exp. 2016, 108, 53658. [CrossRef] [PubMed]
67. Serrano-Perez, MC; Martin, ED; Vaquero, CF; Azcoitia, ib.; Calvo, S.; Cano, E.; Tranque, P. Teb lus teb ntawm qhov tseem ceeb ntawm NFATc3 rau excitotoxic thiab traumatic lub hlwb insults: Kev txheeb xyuas ntawm ib tug subpopulation ntawm reactive astrocytes. Glia 2011, 59, 94–107. [CrossRef]
68. Fradejas, N.; Serrano-Perez Mdel, C.; Tranque, P.; Calvo, S. Selenoprotein S qhia nyob rau hauv reactive astrocytes tom qab lub hlwb raug mob. Glia 2011, 59, 959–972. [CrossRef]






